IMP metallo-β-lactamase-producing clinical isolates of Enterobacter cloacae in the UK

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 6, 2011, Pages 1408-1409

  Shet, V ^a   Gouliouris, T ^a   Brown, N M ^a   Turton, J F ^b   Zhang, J ^b   Woodford, N ^b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Carbapenemases; Carbapenems; Enterobacteriaceae

Indexed keywords

AMIKACIN; BETA LACTAMASE AMPC; CARBAPENEM DERIVATIVE; CARBAPENEMASE; COLISTIN; ERTAPENEM; GENTAMICIN; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; METALLO BETA LACTAMASE IMP; PORIN; TIGECYCLINE; TOBRAMYCIN; UNCLASSIFIED DRUG;

AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIUM ISOLATE; ENTEROBACTER CLOACAE; ENZYME SYNTHESIS; GENETIC VARIABILITY; GRAM NEGATIVE BACTERIUM; HOSPITAL ADMISSION; HUMAN; INFECTION; INTENSIVE CARE UNIT; LETTER; MICROBIOLOGICAL EXAMINATION; POLYMERASE CHAIN REACTION; PROTEIN DEPLETION; UNITED KINGDOM;

BACTERIAL TYPING TECHNIQUES; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; DNA, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE INFECTIONS; GREAT BRITAIN; HUMANS; MOLECULAR TYPING;

EID: 79956043251     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr078     Document Type: Letter

References (6)

1. Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev 2007; 20: 440-58.
2. Doumith M, Ellington MJ, Livermore DM, et al. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother 2009; 63: 659-67.
3. Andrews JM. BSAC Susceptibility Testing Guide. Chapter 2. Determination of minimum inhibitory concentrations. http://www.bsac.org.uk/Resources/BSAC/Chapter_2_Determination_of_MICs_2006.pdf (23 February 2011, date last accessed).
4. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009; 9: 228-36.
5. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis August 2010; 10: 597-602.
6. Nordmann P, Poirel L, Toleman MA, et al. Does broad-spectrum b-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? J Antimicrob Chemother 2011; 66: 689-92.